Continuous Use of Gilenya for Up to 3 Years Can Lead to 50% Drop in Annual Relapse Rates, Real-world Study Says

15 February 2019

Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients who began treatment with Gilenya (fingolimod) and stayed with it continuously showed a more than 50 percent reduction in annual relapse rates, a real-world study following these people for up to three years found.

Results were reported in the study “Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis,” published in the Journal of the Neurological Sciences.

Gilenya, marketed by Novartis, is an oral disease-modifying treatment for relapsing-remitting multiple sclerosis (RRMS), approved in 2010. It acts by binding and modulating receptors — called sphingosine-1-phosphate receptor — on lymphocytes (adaptive immune cells). Read on. 

.

Blog categories: 

Category

Archive